January 2008
BioWorld Today;1/7/2008, Vol. 19 Issue 4, p5
This section offers news briefs on the biopharmaceutics industry. Preliminary data were reported by Anadys Pharmaceuticals Inc. from studies of ANA598 non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase. BioMarin Pharmaceuticals Inc. and Genzyme Corp. have restructured their venture regarding Aldurazyme for mucopolysaccharidosis I. Meanwhile, a preclinical antibody program was launched by Genmab A/S aimed at targeting the CD32b receptor.


Related Articles

  • BIOMARIN FILES CTX TO CONDUCT CLINICAL TRIAL OF VIBRIOLYSIN.  // Worldwide Biotech;Aug2001, Vol. 13 Issue 8, p5 

    Reports that BioMarin Pharmaceutical Inc. has filed a Clinical Trial Exemption application with the Medicines Control Agency in the United Kingdom for permission to conduct a human clinical trial of Vibriolysin Topical in patients with serious burns.

  • BIOMARIN INITIATES PHASE 2 CLINICAL TRIAL OF ARYPLASE.  // Biotech Business;Jun2002, Vol. 15 Issue 6, p1 

    Reports on the initiation by Biomarin Pharmaceutical Inc. of the second phase clinical trial for its Aryplase drug.

  • BioMarin/Genzyme to Conduct Confirmatory Trial of Aldurazyme.  // Biotech Business;Jan2000, Vol. 13 Issue 1, p1 

    Reports that BioMarin Pharmaceutical Inc. and joint venture partner Genzyme General will conduct a confirmatory clinical trial of Aldurazyme enzyme replacement therapy for mucopolysaccharidosis-I.

  • BioMarin and Igan collaborate to develop enzyme for nephropathy.  // PharmaWatch: Biotechnology;Jan2008, Vol. 7 Issue 1, p15 

    The article reports on the collaborative program between BioMarin Pharmaceutical Inc. and Igan Biosciences which aims to develop an IgA protease for treating IgA nephropathy. Igan Chairman Andrew Plaut said that IgA proteases can reverse or prevent the progression of IgA nephropathy and...

  • Active Pharmaceutical Ingredients Watch.  // Chemical Market Reporter;5/12/2003, Vol. 263 Issue 19, p15 

    Reports developments related to pharmaceutical industries in the U.S. as of May 2003. Approval for Aldurazyme to treat mucopolysaccharidosis from Biomarin Pharmaceutical Inc. and Genzyme General Corp.; Application for non-Hodgkin's lymphoma drug Bexxar from Corixa Corp.; Net loss of Elan Corp.

  • Clinic Roundup.  // BioWorld Today;1/4/2012, Vol. 23 Issue 2, p7 

    This section offers news briefs on clinical trials. Affitech A/S of Denmark and Russian partner IBC Generium submitted an application to the Russian Health Authority to begin a Phase II trial with the former's lead monoclonal antibody candidate AT001/r84. Ampio Pharmaceuticals Inc. completed the...

  • AASLD 2010.  // BioWorld Today;11/2/2010, Vol. 21 Issue 212, p8 

    The article reports that Anadys Pharmaceuticals Inc. presented the clinical trial results of its ANA598 direct-acting antiviral which showed an acceleration of virus levels in patients.

  • Anadys Reports Good Phase II HCV Data.  // Bioworld Week;3/1/2010, Vol. 18 Issue 9, p5 

    The article focuses on the findings of the Phase II clinical trial conducted by San Diego, California-based Anadys Pharmaceuticals Inc. which showed that its compound for hepatitis C reduced the virus to undetectable levels after 12 weeks and saw no viral rebound when combined with standard care...

  • Laronidase.  // BioDrugs;2002, Vol. 16 Issue 4, p316 

    Adis Comments BioMarin Pharmaceutical is developing laronidase, recombinant α-L-iduronidase enzyme replacement therapy for the treatment of mucopolysaccharidosis I (MPS-I) [the most severe form of this is called Hurler syndrome]. The company has received US and European orphan drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics